special/viewpoint

The Global Drug Gap

+ See all authors and affiliations

Science  17 Mar 2000:
Vol. 287, Issue 5460, pp. 1979-1981
DOI: 10.1126/science.287.5460.1979

You are currently viewing the abstract.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Abstract

Global inequities in access to pharmaceutical products exist between rich and poor countries because of market and government failures as well as huge income differences. Multiple policies are required to address this global drug gap for three categories of pharmaceutical products: essential drugs, new drugs, and yet-to-be-developed drugs. Policies should combine “push” approaches of financial subsidies to support targeted drug development, “pull” approaches of financial incentives such as market guarantees, and “process” approaches aimed at improved institutional capacity. Constructive solutions are needed that can both protect the incentives for research and development and reduce the inequities of access.

  • * To whom correspondence should be addressed. E-mail: reich{at}hsph.harvard.edu

View Full Text

Related Content